Abvc Biopharma (ABVC) Finished Goods (2018 - 2019)
Abvc Biopharma's (ABVC) quarterly Finished Goods came in at $94727.0 in Q4 2019, down 5.97% YoY from $100736.0 in Q4 2018, and up 3.71% on a QoQ basis from $91341.0 in Q3 2019.
Abvc Biopharma (ABVC) Finished Goods (2018 - 2019) Analysis & Trends
Abvc Biopharma (ABVC) has 2 years of Finished Goods data on file, last reported at $94727.0 in Q4 2019.
- Quarterly Finished Goods fell 5.97% year-over-year to $94727.0 in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $94727.0 (down 5.97% YoY) and the FY2019 annual result came in at $94727.0, down 5.97% from the prior year.
- Finished Goods grew to $94727.0 in Q4 2019, from $91341.0 in the prior quarter.
- In the past five years, Finished Goods ranged from a high of $100736.0 in Q4 2018 to a low of $91324.0 in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.54 Bn | 130.69 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.89 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.65 Bn | 1.37 Bn |
| 4 | Moderna | 56.53 Bn | 51.39 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Abvc Biopharma | 22.93 Mn | 22.93 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 94,727.00 |
| Sep 30, 2019 | 91,341.00 |
| Jun 30, 2019 | 91,324.00 |
| Mar 31, 2019 | 91,891.00 |
| Dec 31, 2018 | 100,736.00 |